Abcam Plc (LON:ABC) reached a new 52-week high during trading on Wednesday after Numis Securities raised their price target on the stock from GBX 1,116 to GBX 1,200. Numis Securities currently has an add rating on the stock. Abcam Plc traded as high as GBX 1,113 ($14.37) and last traded at GBX 1,097 ($14.17), with a volume of 426,082 shares trading hands. The stock had previously closed at GBX 1,082 ($13.97).
A number of other research firms have also recently commented on ABC. Peel Hunt reissued a “hold” rating and set a GBX 750 ($9.69) target price on shares of Abcam Plc in a research report on Friday, August 18th. Berenberg Bank reissued a “buy” rating and set a GBX 1,100 ($14.21) target price on shares of Abcam Plc in a research report on Monday. Panmure Gordon reissued a “sell” rating on shares of Abcam Plc in a research report on Monday. Finally, J P Morgan Chase & Co reissued a “neutral” rating and set a GBX 864 ($11.16) target price on shares of Abcam Plc in a research report on Tuesday. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and one has given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of GBX 914 ($11.80).
The stock has a 50-day moving average price of GBX 1,052.08 and a 200-day moving average price of GBX 953.19. The company’s market capitalization is GBX 2.22 billion.
TRADEMARK VIOLATION NOTICE: “Abcam Plc (ABC) Hits New 12-Month High Following Analyst Upgrade” was posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this article on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The legal version of this article can be accessed at https://stocknewstimes.com/2017/09/13/abcam-plc-abc-hits-new-12-month-high-following-analyst-upgrade.html.
About Abcam Plc
Abcam plc is a global life sciences company. As a developer of reagents and tools, the Company’s purpose is to serve life science researchers globally. Providing the research and clinical communities with tools and scientific support, the Company offers validated biological binders and assays to address important targets in critical biological pathways.
Receive News & Ratings for Abcam Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam Plc and related companies with MarketBeat.com's FREE daily email newsletter.